Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 252

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part II, Item 1A
Chunk 252
---
Item 1A.    Risk Factors.

Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report and in the Annual Report on Form 10-K that we filed with the SEC on February 12, 2025, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our Class A common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows and prospects. In such an event, the market price of our Class A common stock could decline and you may lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our Class A common stock. In addition, you should consider the interrelationship and compounding effects of multiple risks occurring simultaneously. 

Summary Risk Factors

Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully below and include, but are not limited to, risks related to:

Risks related to our business and industry:

•Fluctuations in our operating results due to a variety of factors;

•Our dependency on the availability of government funding to and research and development spending by research institutions;

•Our ability to compete effectively;

•Our pricing strategy;

•Trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers;

•Our ability to increase penetration into our existing customer segments and to maintain and increase the effectiveness of our commercial organization;

•The size of the market for our solutions;

•The complexity of data generated by our products;

•Our ability to effectively manage product transitions and forecast customer demand, including for both existing and newly introduced products;

24

Table of Contents

•Our ability to generate sufficient revenue, to attain cash flows from operating activities in excess of our capital investment requirements and to achieve and maintain profitability;

•Our ability to consistently manufacture our products to necessary specifications in necessary quantities and at acceptable cost and performance level;

•Our ability to develop new products or new versions of existing products and enhance the capabilities of our existing products